September 2, 2025 at 7:11 pm
Ambusol AB (publ) has entered an exclusive global licensing and development agreement with Fluicell AB (publ), granting Ambusol worldwide rights to apply Fluicell’s microfluidic technology in cancer treatment. The partnership provides Ambusol with a unique platform for precise delivery of therapeutic compounds directly into tumors, initially targeting glioblastoma, with expansion into additional cancer indications. The collaboration strengthens Ambusol’s position in precision oncology and includes joint development of new IP owned by Ambusol.